Chapter 40: Drugs Affecting the Female Reproductive System

Key drug categories include sex hormones (estrogens and progestins), Estrogen Receptor Modulators (ERMs), fertility agents, and uterine motility drugs. Estrogens are crucial for the development of the female reproductive system and secondary sex characteristics, regulating the release of pituitary FSH and LH, promoting bone formation, and contributing to the proliferation of the endometrial lining. Clinically, estrogens are utilized for hormone replacement therapy (HRT) in small doses when ovarian activity is absent, to treat symptoms of menopause, manage female hypogonadism and ovarian failure, and serve as components in combination contraceptives. However, extensive research, notably the Women’s Health Initiative, revealed that long-term HRT (greater than 5 years) carries an increased risk of cardiovascular (CV) disease, stroke, blood clots, and certain cancers, leading to the current recommendation that HRT should primarily be limited to short-term use (fewer than 5 years) for symptom reduction. Progestins (such as norethindrone and medroxyprogesterone) are vital for maintaining pregnancy and secondary sex characteristics, and are pharmacologically used in contraceptives (often in combination with estrogens to prevent follicle maturation and ovulation), or to treat amenorrhea and functional uterine bleeding. Estrogens and progestins are metabolized hepatically and excreted in the urine, and share similar contraindications, including a history of thromboembolic disorders or estrogen-dependent cancers. Estrogen Receptor Modulators (ERMs), such as raloxifene, are non-hormonal agents designed to stimulate beneficial estrogen effects (like increasing bone mineral density for osteoporosis prevention) while minimizing adverse effects like endometrial stimulation. Fertility drugs (like clomiphene and menotropins) are prescribed to women with functioning ovaries who are unable to conceive, working to stimulate ovarian follicular development and maturation by increasing FSH and LH levels. Patients using these agents must be cautioned about the greatly increased risk of multiple births and ovarian overstimulation. Finally, Uterine Motility Drugs regulate contractions: Oxytocics (oxytocin and methylergonovine) stimulate uterine contraction, used to induce labor, reinforce contractions, or prevent postpartum hemorrhage; conversely, Tocolytics (hydroxyprogesterone caproate is currently approved) relax the uterine smooth muscle to prevent preterm labor. Abortifacients (like dinoprostone and mifepristone) strongly stimulate uterine activity for evacuation of uterine contents, used typically between 12 and 20 weeks of pregnancy. Throughout treatment with drugs affecting the female reproductive system, nursing considerations emphasize annual physical and pelvic examinations, careful monitoring for signs of thromboembolism, support regarding the complex emotional issues associated with fertility treatment or abortion, and strict patient teaching, including advising against smoking due to the significantly increased risk of thrombotic events when combined with hormone therapy.